MCL1 and acute myeloid leukemia: The dual AXL/MERTK inhibitor ONO-7475 has demonstrated efficacy in targeting FLT3-mutant AML cells by inhibiting key signaling pathways involving ERK and MCL-1, which are implicated in drug resistance against venetoclax [113].